Furthermore, neither Rosa26_Alkal2;Th-MYCN nor Alk-F1178S;Th-MYCN NB mouse tumours harbour genetic abnormalities syntenic to human 11q deletions that would support increased sensitivity to ATRi treatment as a result of decreased ATM or other DDR response component activity49. This evidence concerns the gene ALK and neoplasm.